Regeneron Pharmaceuticals Share Price (NASDAQ: REGN)

$588.69

▲

1.04

(0.18%)

Live

Last updated on August 27, 2025 at 10:37 pm IST

$₹

Check the interactive Regeneron Pharmaceuticals Stock chart to analyse performance

Regeneron Pharmaceuticals stock performance

as on August 27, 2025 at 10:37 pm IST

Today's Low:$586.80
Today's High:$595.39
$588.69
0.32%
Downside
Day's Volatility :1.44%
Upside
1.13%
52 Weeks Low:$476.49
52 Weeks High:$1,211.20
$588.69
19.06%
Downside
52 Weeks Volatility :60.66%
Upside
51.4%

Regeneron Pharmaceuticals Stock Returns

Period	Regeneron Pharmaceuticals, Inc.	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	-0.74%	3.7%	12.2%
6 Months	-16.9%	-6.9%	16.2%
1 Year	-51.12%	-11.9%	21.3%
3 Years	-0.89%	7.7%	77.4%

Regeneron Pharmaceuticals, Inc. Key Stats

Check Regeneron Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$587.65
Open	$572.0
Today's High	$595.39
Today's Low	$586.44
Market Capitalization	$62.5B
Today's Volume	$1.6M
52 Week High	$1211.1999
52 Week Low	$476.4869
Revenue TTM	$14.2B
EBITDA	$4.5B
Earnings Per Share (EPS)	$39.67
PE Ratio	14.86
Dividend Yield	0.29%
Profit Margin	31.37%
Quarterly Earnings Growth YOY	0.03%
Return On Equity TTM	15.34%

Stock Returns calculator for Regeneron Pharmaceuticals Stock including INR - Dollar returns

The Regeneron Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Regeneron Pharmaceuticals investment value today

Current value as on today

₹53,573

Returns

₹46,427

(-46.43%)

Returns from Regeneron Pharmaceuticals Stock

₹51,014 (-51.01%)

Dollar Returns*

₹4,587 (+4.59%)

Indian investors sentiment towards Regeneron Pharmaceuticals Stock

6.67%

Period: Jul 27, 2025 to Aug 26, 2025. Change in 30 Days versus previous period

Investment in Regeneron Pharmaceuticals Shares from India has grown by 6.67% over the past 30 days, indicating increased transactional activity.

52%

Period: Jul 27, 2025 to Aug 26, 2025. Change in 30 Days versus previous period

Search interest for Regeneron Pharmaceuticals Stock from India on INDmoney has increased by 52% in the last 30 days, reflecting an upward trend in search activity.

Indian Mutual Funds that invest in Regeneron Pharmaceuticals Stock

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	839	-5.11	0.10%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	168	0.00	0.48%
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	1511	-49.42	0.33%

Global Institutional Holdings in Regeneron Pharmaceuticals, Inc.

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
8.89%
BlackRock Inc
8.42%
FMR Inc
7.17%
JPMorgan Chase & Co
5.34%
State Street Corp
4.52%
Dodge & Cox
3.61%

Analyst Recommendation on Regeneron Pharmaceuticals Stock

Rating

Trend

Buy

76%Buy

20%Hold

2%Sell

Based on 34 Wall street analysts offering stock ratings for Regeneron Pharmaceuticals(by analysts ranked 0 to 5 stars)

Regeneron Pharmaceuticals Share Price Target

What analysts predicted

Upside of 21.76%

Target:

$716.78

Current:

$588.69

Regeneron Pharmaceuticals share price target is $716.78, a slight Upside of 21.76% compared to current price of $588.69 as per analysts' prediction.

Regeneron Pharmaceuticals Stock Insights

Price Movement
In the last 7 days, REGN stock has moved down by -0.6%
Increasing Revenue
Regeneron Pharmaceuticals, Inc. has shown strong revenue growth in the last two quarters. Revenue increased from $3.02 billion to $3.67 billion, reflecting an average increase of 17.6% per quarter.
Increasing Net Profit
Regeneron Pharmaceuticals, Inc. has shown strong profit performance over the last two quarters. The net profit increased from $808.7 million to $1.39 billion, marking an average growth of 41.9% per quarter.
REGN vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 61.0% return, outperforming this stock by 112.1%
REGN vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 113.9% return, outperforming this stock by 115.4%
Price to Sales
Regeneron Pharmaceuticals, Inc. has a Price-to-Sales Ratio of 4.4, meaning investors are willing to pay $4.4 for every $1 of sales the company generates. In contrast, Alnylam Pharmaceuticals, Inc. has a significantly higher Price-to-Sales Ratio of 23.7, indicating that investors are willing to pay $23.7 for every $1 of sales. This suggests that Regeneron may be seen as less expensive relative to its sales compared to Alnylam.

Regeneron Pharmaceuticals, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$7.9B	↑ 17.18%
Net Income	$2.1B	↓ 13.44%
Net Profit Margin	26.91%	↓ 9.51%

	FY20	Y/Y Change
Revenue	$8.5B	↑ 8.06%
Net Income	$3.5B	↑ 66.05%
Net Profit Margin	41.35%	↑ 14.44%

	FY21	Y/Y Change
Revenue	$16.1B	↑ 89.14%
Net Income	$8.1B	↑ 129.86%
Net Profit Margin	50.25%	↑ 8.9%

	FY22	Y/Y Change
Revenue	$12.2B	↓ 24.26%
Net Income	$4.3B	↓ 46.28%
Net Profit Margin	35.64%	↓ 14.61%

	FY23	Y/Y Change
Revenue	$13.1B	↑ 7.76%
Net Income	$4.0B	↓ 8.87%
Net Profit Margin	30.14%	↓ 5.5%

	FY24	Y/Y Change
Revenue	$14.2B	↑ 8.27%
Net Income	$4.4B	↑ 11.61%
Net Profit Margin	31.07%	↑ 0.93%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$3.1B	↓ 8.42%
Net Income	$722.0M	↓ 37.74%
Net Profit Margin	22.96%	↓ 10.81%

	Q2 FY24	Q/Q Change
Revenue	$3.5B	↑ 12.79%
Net Income	$1.4B	↑ 98.38%
Net Profit Margin	40.38%	↑ 17.42%

	Q3 FY24	Q/Q Change
Revenue	$3.7B	↑ 4.89%
Net Income	$1.3B	↓ 6.4%
Net Profit Margin	36.03%	↓ 4.35%

	Q4 FY24	Q/Q Change
Revenue	$3.8B	↑ 1.84%
Net Income	$917.7M	↓ 31.55%
Net Profit Margin	24.22%	↓ 11.81%

	Q1 FY25	Q/Q Change
Revenue	$3.0B	↓ 20.07%
Net Income	$808.7M	↓ 11.88%
Net Profit Margin	26.7%	↑ 2.48%

	Q2 FY25	Q/Q Change
Revenue	$3.7B	↑ 21.36%
Net Income	$1.4B	↑ 72.08%
Net Profit Margin	37.86%	↑ 11.16%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$7.1B	↑ 12.82%

	FY20	Y/Y Change
Profit	$7.1B	↑ 0.85%

	FY21	Y/Y Change
Profit	$13.3B	↑ 86.91%

	FY22	Y/Y Change
Profit	$10.5B	↓ 21.58%

	FY23	Y/Y Change
Profit	$12.2B	↑ 16.87%

	FY24	Y/Y Change
Profit	$11.8B	↓ 3.95%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$2.6B	↓ 7.42%

	Q2 FY24	Q/Q Change
Profit	$2.9B	↑ 13.44%

	Q3 FY24	Q/Q Change
Profit	$3.1B	↑ 5.49%

	Q4 FY24	Q/Q Change
Profit	$3.1B	↓ 0.33%

	Q1 FY25	Q/Q Change
Profit	$2.4B	↓ 21.31%

	Q2 FY25	Q/Q Change
Profit	$3.0B	↑ 23.5%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$2.4B	↑ 10.7%
Investing Cash Flow	$-2.0B	↑ 38.61%
Financing Cash Flow	$-252.1M	↑ 226.98%

	FY20	Y/Y Change
Operating Cash Flow	$2.6B	↑ 7.74%
Investing Cash Flow	$-70.6M	↓ 96.52%
Financing Cash Flow	$-2.0B	↑ 681.63%

	FY21	Y/Y Change
Operating Cash Flow	$7.1B	↑ 170.47%
Investing Cash Flow	$-5.4B	↑ 7527.05%
Financing Cash Flow	$-1.0B	↓ 48.96%

	FY22	Y/Y Change
Operating Cash Flow	$5.0B	↓ 29.18%
Investing Cash Flow	$-3.8B	↓ 29.72%
Financing Cash Flow	$-1.0B	↑ 0.32%

	FY23	Y/Y Change
Operating Cash Flow	$4.6B	↓ 8.39%
Investing Cash Flow	$-3.2B	↓ 15.84%
Financing Cash Flow	$-1.8B	↑ 77.41%

	FY24	Y/Y Change
Operating Cash Flow	$4.4B	↓ 3.78%
Investing Cash Flow	$-2.5B	↓ 22.51%
Financing Cash Flow	$-2.2B	↑ 22.93%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$1.5B	↑ 38.8%
Investing Cash Flow	$-1.7B	↑ 2448.49%
Financing Cash Flow	$47.1M	↓ 110.56%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$354.0M	↓ 76.6%
Investing Cash Flow	$-557.2M	↓ 66.97%
Financing Cash Flow	$-478.1M	↓ 1115.07%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$1.3B	↑ 264.75%
Investing Cash Flow	$-574.4M	↑ 3.09%
Financing Cash Flow	$-634.0M	↑ 32.61%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$1.3B	↓ 2.2%
Investing Cash Flow	$350.6M	↓ 161.04%
Financing Cash Flow	$-1.1B	↑ 79.1%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$1.0B	↓ 17.24%
Investing Cash Flow	$647.5M	↑ 84.68%
Financing Cash Flow	$-1.1B	↓ 4.08%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$1.1B	↑ 9.5%
Investing Cash Flow	$-1.1B	↓ 268.96%
Financing Cash Flow	$-1.1B	↑ 3.58%

Regeneron Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Regeneron Pharmaceuticals is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Regeneron Pharmaceuticals, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Regeneron Pharmaceuticals, Inc.	5.16%	-16.9%	-51.12%	-0.89%	-2.51%
Beone Medicines Ltd	4.54%	18.87%	52.28%	84.02%	26.72%
Vertex Pharmaceuticals Incorporated	-16.02%	-19.22%	-19.42%	37.43%	43.36%
Alnylam Pharmaceuticals, Inc.	38.9%	84.99%	60.96%	115.82%	243.29%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Regeneron Pharmaceuticals, Inc.	14.86	14.86	1.21	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.29	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.64	27.64	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Regeneron Pharmaceuticals, Inc.	Buy	$62.5B	-2.51%	14.86	31.37%
Beone Medicines Ltd	NA	$38.3B	26.72%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$99.7B	43.36%	27.64	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$58.2B	243.29%	NA	-12.96%

Regeneron Pharmaceuticals Dividend announcements

Regeneron Pharmaceuticals Dividends September, 2025
In the quarter ending September,2025. Regeneron Pharmaceuticals has declared dividend of $0.88

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Organization	Regeneron Pharmaceuticals
Employees	15182
CEO	Dr. Leonard S. Schleifer M.D., Ph.D.
Industry	Health Technology

Key Management of Regeneron Pharmaceuticals, Inc.

Name	Title
Dr. Leonard S. Schleifer M.D., Ph.D.	Co-Founder, President, CEO & Co-Chairman
Dr. George D. Yancopoulos M.D., Ph.D.	Co-Founder, President, Chief Scientific Officer & Co-Chairman
Mr. Christopher R. Fenimore CPA	Executive VP of Finance & CFO
Dr. Andrew J. Murphy Ph.D.	Executive Vice President of Research
Mr. Daniel P. Van Plew	Executive VP and GM of Industrial Operations & Product Supply
Mr. Rajesh Ahuja	Senior Vice President of Quality Assurance & Operations
Mr. Bob McCowan	Senior VP of IT & Chief Information Officer
Mr. Ryan Crowe	Senior Vice President of Investor Relations & Strategic Analysis
Mr. Joseph J. LaRosa J.D.	Executive VP, General Counsel & Secretary
Ms. Melissa Lozner	Senior VP & Chief Compliance Officer

Important FAQs about investing in REGN Stock from India :

What is Regeneron Pharmaceuticals share price today?

Regeneron Pharmaceuticals share price today is $588.69 as on August 27, 2025 at 10:37 pm IST. Regeneron Pharmaceuticals share today touched a day high of $595.39 and a low of $586.80.

What is the 52 week high and 52 week low for Regeneron Pharmaceuticals share?

Regeneron Pharmaceuticals share touched a 52 week high of $1,211.20 and a 52 week low of $476.49. Regeneron Pharmaceuticals stock price today i.e. August 27, 2025 at 10:37 pm IST is trending at $588.69, lower by 51.4% versus the 52 week high.

How to invest in Regeneron Pharmaceuticals Stock (REGN) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Regeneron Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Regeneron Pharmaceuticals Shares that will get you 0.0025 shares as per Regeneron Pharmaceuticals share price of $588.69 per share as on August 27, 2025 at 10:37 pm IST.

What is the minimum amount required to buy Regeneron Pharmaceuticals Stock (REGN) from India?

Indian investors can start investing in Regeneron Pharmaceuticals (REGN) shares with as little as ₹87.788 or $1 (as of August 27, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹877.88 in Regeneron Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 27, 2025). Based on Regeneron Pharmaceuticals share’s latest price of $588.69 as on August 27, 2025 at 10:37 pm IST, you will get 0.0170 shares of Regeneron Pharmaceuticals. Learn more about fractional shares .

What are the returns that Regeneron Pharmaceuticals has given to Indian investors in the last 5 years?

Regeneron Pharmaceuticals stock has given -2.51% share price returns and 18.79% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?